| scholarly article | Q13442814 |
| P50 | author | Helena Genberg | Q80151939 |
| P2093 | author name string | Torbjörn Lundgren | |
| Gunilla Kumlien | |||
| Gunnar Tydén | |||
| John Sandberg | |||
| Ingela Fehrman | |||
| P2860 | cites work | ABO-incompatibility in solid organ transplantation | Q34352971 |
| Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics | Q35745999 | ||
| ABO-incompatible kidney transplantation using both A2 and non-A2 living donors | Q44077744 | ||
| Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab | Q44584381 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney transplantation | Q740909 |
| P304 | page(s) | 145-148 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab | |
| P478 | volume | 5 |
| Q34439147 | A case of nearly mistaken AB para-Bombay blood group donor transplanted to a group 'O' recipient. |
| Q51171028 | A new generation of carbohydrate-based therapeutics: recombinant mucin-type fusion proteins as versatile inhibitors of protein-carbohydrate interactions. |
| Q50905754 | A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. |
| Q35607565 | ABO Incompatible Kidney Transplantation-Current Status and Uncertainties |
| Q37803412 | ABO blood group incompatibility: a diminishing barrier to successful kidney transplantation? |
| Q40879749 | ABO desensitization affects cellular immunity and infection control after renal transplantation |
| Q40915460 | ABO-Incompatible Living Kidney Transplants: Evolution of Outcomes and Immunosuppressive Management |
| Q36578386 | ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation |
| Q84820579 | ABO-incompatible kidney transplantation |
| Q36696495 | ABO-incompatible renal transplantation in developing world - crossing the immunological (and mental) barrier. |
| Q46452348 | ABO-incompatible renal transplantation--why and how? |
| Q38325273 | Adsorption of chain type-specific ABO antibodies on Sepharose-linked A and B tetrasaccharides |
| Q41845634 | Adult Living Donor Liver Transplantation with ABO-Incompatible Grafts: A German Single Center Experience |
| Q38544529 | Advances in pharmacotherapy to treat kidney transplant rejection |
| Q51101952 | American society of transplantation symposium on B cells in transplantation: harnessing humoral immunity from rodent models to clinical practice. |
| Q42951982 | An Integrative Approach for the Transplantation of High-Risk Sensitized Patients |
| Q38267202 | An update on ABO-incompatible kidney transplantation |
| Q37332696 | Antibody-mediated rejection: treatment alternatives and outcomes. |
| Q92112007 | Association Between Peripheral Blood CD19-Positive Rate and Antibody-Mediated Rejection Following Rituximab Administration in Kidney Transplant Recipients |
| Q38189360 | B cell depletion: rituximab in glomerular disease and transplantation |
| Q37782255 | B cells and transplantation tolerance |
| Q36429791 | B cells: a rational target in alloantibody-mediated solid organ transplantation rejection |
| Q33697381 | Baseline Anti-blood Group Antibody Titers and their Response to Desensitization and Kidney Transplantation |
| Q34901704 | Behaviour of non-donor specific antibodies during rapid re-synthesis of donor specific HLA antibodies after antibody incompatible renal transplantation. |
| Q37820338 | Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach |
| Q37994745 | Beyond dialysis: current and emerging blood purification techniques. |
| Q50996014 | Bortezomib in ABO-incompatible kidney transplant desensitization: a case report. |
| Q36304925 | Characteristics of protein-carbohydrate interactions as a basis for developing novel carbohydrate-based antirejection therapies |
| Q90047669 | Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis |
| Q39452807 | Clinical outcomes with ABO antibody titer variability in a multicenter study of ABO-incompatible kidney transplantation in the United Kingdom |
| Q41258755 | Combined induction therapy with rabbit antithymocyte globulin and rituximab in highly sensitized renal recipients |
| Q39716270 | Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. |
| Q37836967 | Current approaches to the management of highly sensitized kidney transplant patients |
| Q36171175 | Current progress in ABO-incompatible kidney transplantation |
| Q98727034 | Current protocols and outcomes of ABO-incompatible kidney transplantation |
| Q64098171 | Current protocols and outcomes of ABO-incompatible kidney transplantation based on a single-center experience |
| Q41731036 | Desensitization with plasmapheresis and anti-Cd20 for ABO incompatible kidney transplantation from living donor: experience of a single center in Italy |
| Q88581940 | Desensitization with the Use of an Antibody Removal-Free Protocol in ABO-Incompatible Kidney Transplant Recipients with a Low Anti-A/B Antibody Titer |
| Q38680131 | Discontinuation of steroids in ABO-incompatible renal transplantation. |
| Q36577151 | Drug insight: rituximab in renal disease and transplantation |
| Q35543289 | Early clinical complications after ABO-incompatible live-donor kidney transplantation: a national study of Medicare-insured recipients. |
| Q50542389 | Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation. |
| Q36400872 | Excellent long term patient and renal allograft survival after ABO-incompatible kidney transplantation: Experience of one center |
| Q80275366 | Experience with laparoscopic splenectomy for ABO-incompatible living renal transplantation without plasmapheresis |
| Q38269416 | Four years of experience with the Australian kidney paired donation programme |
| Q40325057 | Glomerular Diseases and Renal Transplantation: Pathogenic Pathways and Evolution of Therapeutic Interventions |
| Q30276550 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue |
| Q34122035 | Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis |
| Q33334832 | Identification and characterization of peptide mimics of blood group A antigen |
| Q37830813 | Immunohaematological and apheretic aspects of the first kidney transplant from a living, ABO-incompatible donor carried out in Italy |
| Q38134066 | Immunosuppressive drug therapy |
| Q42776229 | Impact of pretransplant intravenous immunoglobulin administration on anti-AB0 antibody levels in AB0-incompatible living donor kidney transplantation |
| Q50983859 | In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. |
| Q54481297 | Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience. |
| Q36967217 | Induction therapy in pediatric renal transplant recipients: an overview |
| Q51787282 | Initial experience with ABO-incompatible live donor renal transplantation. |
| Q37776364 | Isoagglutinin adsorption in ABO-incompatible transplantation |
| Q50755303 | Isotype-specific detection of ABO blood group antibodies using a novel flow cytometric method. |
| Q37305391 | Japan's experience with living-donor kidney transplantation across ABO barriers |
| Q38258064 | Kidney paired donation: principles, protocols and programs |
| Q88087346 | Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil |
| Q90112402 | Latest insights on ABO-incompatible living-donor renal transplantation |
| Q37080689 | Living donor transplant options in end-stage renal disease patients with ABO incompatibility |
| Q38172280 | Molecular deciphering of the ABO system as a basis for novel diagnostics and therapeutics in ABO incompatible transplantation |
| Q38102315 | New perspectives of immunosuppression. |
| Q36802609 | New treatments for acute humoral rejection of kidney allografts |
| Q95654130 | Outcome of ABO Blood Type-Incompatible Living-Related Donor Kidney Transplantation Under a Contemporary Immunosuppression Strategy in Japan |
| Q40245497 | Outcomes and risk stratification for late antibody-mediated rejection in recipients of ABO-incompatible kidney transplants: a retrospective study |
| Q45027158 | Outcomes of pediatric ABO-incompatible kidney transplantations are equivalent to ABO-compatible controls |
| Q51830578 | Post-Transplantation Immunoadsorption Can Be Withheld in ABO-Incompatible Kidney Transplant Recipients. |
| Q53007079 | Postoperative rebound of antiblood type antibodies and antibody-mediated rejection after ABO-incompatible living-related kidney transplantation. |
| Q44632269 | Potent immunosuppression for ABO-incompatible renal transplantation may not be a risk factor for malignancy. |
| Q38010231 | Prevention of antibody-mediated kidney transplant rejection |
| Q26830899 | Principles of separation: indications and therapeutic targets for plasma exchange |
| Q50484739 | Production of anti-ABO blood group antibodies after minor ABO-incompatible bone marrow transplantation in NOD/SCID/gamma(c)(null) mice. |
| Q37170056 | Production of human blood group B antigen epitope conjugated protein in Escherichia coli and utilization of the adsorption blood group B antibody |
| Q43501601 | Progressive multifocal leuko-encephalopathy after ABO-incompatible kidney transplantation |
| Q36173541 | Rational clinical trial design for antibody mediated renal allograft injury. |
| Q36861300 | Recent findings in ABO-incompatible kidney transplantation: classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodation |
| Q45746615 | Renal transplantation in infants and small children |
| Q37163080 | Renal transplantation today |
| Q44474312 | Response to Kute: 'facilitators to national kidney paired donation program'. |
| Q41527816 | Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. |
| Q33370836 | Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action |
| Q48511018 | Safety and Efficacy of Induction Therapy With Thymoglobulin in AB0-Incompatible Kidney Transplantation |
| Q89029586 | Similar Microvascular Inflammation and Tubulointerstitial Injury in ABO-Incompatible and Matched ABO-Compatible Kidney Allografts |
| Q80485421 | Simple "closed-circuit" group-specific immunoadsorption system for ABO-incompatible kidney transplants |
| Q42873915 | Specific antibody filter (SAF) binding capacity enhancement to remove anti‐A antibodies |
| Q39025342 | Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up |
| Q37078119 | Successful renal transplantation with desensitization in highly sensitized patients: a single center experience |
| Q44821162 | Successful treatment of severe ABO antibody-mediated rejection using bortezomib: a case report |
| Q35925181 | Synthetic blood group antigens for anti-A removal device and their interaction with monoclonal anti-A IgM. |
| Q50857922 | The effect of different apheresis modalities on coagulation factor XIII level during antibody removal in ABO-blood type incompatible living related renal transplantation. |
| Q40670409 | The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation. |
| Q36530278 | The emerging role of rituximab in organ transplantation |
| Q30455087 | The role of therapeutic apheresis in high immunologic risk renal transplantation: a review of current trends |
| Q39852578 | The use of original ex vivo immunoadsorption and “multi-manner” apheresis in ABO/H-mismatched kidney transplants—A phase II clinical study |
| Q92326155 | Therapeutic Immunoadsorption and Conventional Plasma Exchange in ABO-incompatible Renal Transplant: An Exculpatory Evidence |
| Q92579417 | Therapeutic Plasma Exchange Practices in Intensive Care Unit |
| Q30456482 | Therapeutic apheresis in kidney transplantation: a review of renal transplant immunobiology and current interventions with apheresis medicine |
| Q36341821 | Therapeutic apheresis--state of the art in the year 2005. |
| Q58551146 | Three Severe Cases of Viral Infections with Post-Kidney Transplantation Successfully Confirmed by Polymerase Chain Reaction and Flow Cytometry |
| Q37390956 | Transfusion medicine and solid organ transplant - Update and review of some current issues |
| Q36379447 | Transplantation across previously incompatible immunological barriers |
| Q37127991 | Treatment of large plasma volumes using specific immunoadsorption to desensitize ABO-incompatible kidney-transplant candidates |
| Q37970443 | Update on the role of rituximab in kidney diseases and transplant |
| Q33396236 | Use of monoclonal antibodies in renal transplantation |
| Q43982164 | Vienna experience of ABO-incompatible living-donor kidney transplantation |
Search more.